[HTML][HTML] A review of broadly protective monoclonal antibodies to treat Ebola virus disease

P Rijal, FR Donnellan - Current Opinion in Virology, 2023 - Elsevier
Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

T Schiffner, I Phung, R Ray, A Irimia, M Tian… - Nature …, 2024 - nature.com
A key barrier to the development of vaccines that induce broadly neutralizing antibodies
(bnAbs) against human immunodeficiency virus (HIV) and other viruses of high antigenic …

De Novo Design of Polyhedral Protein Assemblies: Before and After the AI Revolution

BB Mallik, J Stanislaw, TM Alawathurage… - …, 2023 - Wiley Online Library
Self‐assembling polyhedral protein biomaterials have gained attention as engineering
targets owing to their naturally evolved sophisticated functions, ranging from protecting …

Neutralizing antibodies to block viral entry and for identification of entry inhibitors

EH Tam, Y Peng, MXY Cheah, C Yan, T Xiao - Antiviral Research, 2024 - Elsevier
Neutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral
infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have …

Computational modeling and prediction of deletion mutants

H Woods, DL Schiano, JI Aguirre, KV Ledwitch… - Structure, 2023 - cell.com
In-frame deletion mutations can result in disease. The impact of these mutations on protein
structure and subsequent functional changes remain understudied, partially due to the lack …

[HTML][HTML] Strategies of rational and structure-driven vaccine design for Arenaviruses

AS Peter, DS Hoffmann, J Klier, CM Lange… - Infection, Genetics and …, 2024 - Elsevier
The COVID-19 outbreak has highlighted the importance of pandemic preparedness for the
prevention of future health crises. One virus family with high pandemic potential are …

[HTML][HTML] Anti-Ebola virus mAb 3A6 with unprecedented potency protects highly viremic animals from fatal outcome and physically lifts its glycoprotein target from the …

E Saphire, ZL Salie, Z Ke, P Halfmann… - Research …, 2023 - ncbi.nlm.nih.gov
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP 1, 2) are the
standard of care for Ebola virus disease (EVD). Anti-GP 1, 2 mAbs targeting the stalk and …

Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5

T Harrison, N Alam, B Farrell, D Quinkert, A Lias, L King… - bioRxiv, 2024 - biorxiv.org
Despite recent success in licencing of two malaria vaccines, there continues to be an urgent
need for improved vaccine immunogens as the world aims for malaria eradication. The …

The outbreak of the Ebola virus: Concerns for the animal-to-human spillover

Z Yang, H Yuan, XX Zhang, J Zhai… - Journal of medical …, 2023 - pubmed.ncbi.nlm.nih.gov
The outbreak of the Ebola virus: Concerns for the animal-to-human spillover The outbreak of
the Ebola virus: Concerns for the animal-to-human spillover J Med Virol. 2023 Jan;95(1):e28398 …